Cost-utility analysis of blinatumomab in pediatric patients with acute lymphoblastic leukemia in Iran
Blinatumomab is a cost-effective treatment strategy for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia B-ALL from an Iranian societal perspective.
Authors
- Zahra Amiri (ORCID: https://orcid.org/0000-0001-8838-5870)
- Aziz Eghbali (ORCID: https://orcid.org/0000-0002-5118-0094)
- Behzad Fatemi (ORCID: https://orcid.org/0000-0001-7912-7546)
- Golara Nikakhtar
Institutions
- Iran University of Medical Sciences (IR)
- Shahid Beheshti University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1080/1750743x.2025.2572957
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00